On March 20, Kangmei Pharmaceutical (600518) announced it planned to make a capital increase in cash of ¥45 million to its wholly-owned subsidiary Shenzhen MCKIN Industry Co., Ltd. (hereinafter referred to as “MCKIN”), with a registered capital of ¥50 million after the increase and 100% of shares held by the company. The capital increase will be mainly used to expand the operation scale of MCKIN and increase its capability of foreign investment and business development in order to meet the needs of expanding sales in health products, according to the announcement. Sales growth of the subsidiary's health products would be beneficial to the establishment of the company's terminal health food brand and the improvement of the company's overall profitability.
- White Paper on Bone and Joint Health of Chinese Consumers 2020
- Yili Dairy launched high-protein yogurt, focusing on sport people
- Sinopharm Xingsha launched the Japan's Champion probiotics
- China has introduced its first policy to support the industrial hemp industry
- Beyond Meat became the first overseas Artificial Meat company to set up a factory in China
- Nongfu Spring's market value exceeded HK $370 billion on its first day
- German infant nutrition brand Amykon launched two probiotics in China
- The revenue of Besunyoung in the first half year is about 610 million yuan
- Jellly candy and powder included in the health food filing dosage form in China
- H&H Group net profit increased by 9% for the first half of year
